Ticagrelor versus prasugrel in patients with acute myocardial infarction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sangwoo | - |
dc.contributor.author | Kim, Yong-Giun | - |
dc.contributor.author | Ann, Soe Hee | - |
dc.contributor.author | Park, Hyun Woo | - |
dc.contributor.author | Suh, Jon | - |
dc.contributor.author | Roh, Jae-Hyung | - |
dc.contributor.author | Cho, Young-Rak | - |
dc.contributor.author | Han, Seungbong | - |
dc.contributor.author | Park, Gyung-Min | - |
dc.date.accessioned | 2022-04-13T03:41:57Z | - |
dc.date.available | 2022-04-13T03:41:57Z | - |
dc.date.created | 2022-04-12 | - |
dc.date.issued | 2021-12-01 | - |
dc.identifier.issn | 0167-5273 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/140198 | - |
dc.description.abstract | Background: Ticagrelor and prasugrel are the mainstay of antithrombotic therapy for patients with acute myocardial infarction (MI). However, direct comparative data on clinical outcomes of potent P2Y12 inhibitors are limited, especially in East Asian populations. We aimed to evaluate the effect of ticagrelor versus prasugrel on clinical outcomes in patients with acute MI. Methods: From the Korean nationwide National Health Insurance database, 10,797 patients with acute MI who received either ticagrelor or prasugrel in combination with aspirin after percutaneous coronary intervention (PCI) were enrolled. The primary outcome was net clinical benefit, defined as a composite of death, MI, stroke, or major bleeding. Secondary outcomes included the individual components of the primary outcome as effectiveness and safety measures. Results: Among 10,797 patients, 9591 (88.8%) received ticagrelor and 1206 (11.2%) received prasugrel. During a median follow-up of 1.8 years, the primary outcome occurred in 1051 (16.6%) and 131 (14.4%) patients in the ticagrelor and prasugrel groups, respectively. In the propensity score matched cohort (n = 5979), the risk for the primary outcome was similar between the two groups (hazard ratio [HR] 0.949 for prasugrel; 95% confidence interval [CI]: 0.780-1.154). The risks for the composite of death, MI, or stroke (HR 0.938; 95% CI: 0.752-1.169) and major bleeding (HR 1.022; 95% CI: 0.709-1.472) were also comparable. Conclusions: In patients with acute MI undergoing PCI, ticagrelor and prasugrel appeared to have similar net clinical benefits. The risks for death, MI, or stroke and major bleeding were not significantly different between the two groups. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject | ASSOCIATION TASK-FORCE | - |
dc.subject | ANTITHROMBOTIC THERAPY | - |
dc.subject | ANTIPLATELET THERAPY | - |
dc.subject | P2Y(12) INHIBITOR | - |
dc.subject | AMERICAN-COLLEGE | - |
dc.subject | ASIAN PATIENTS | - |
dc.subject | CLOPIDOGREL | - |
dc.subject | GUIDELINE | - |
dc.subject | MANAGEMENT | - |
dc.title | Ticagrelor versus prasugrel in patients with acute myocardial infarction | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Seungbong | - |
dc.identifier.doi | 10.1016/j.ijcard.2021.09.063 | - |
dc.identifier.scopusid | 2-s2.0-85116402250 | - |
dc.identifier.wosid | 000757375800004 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CARDIOLOGY, v.344, pp.25 - 30 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 344 | - |
dc.citation.startPage | 25 | - |
dc.citation.endPage | 30 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject.keywordPlus | ASSOCIATION TASK-FORCE | - |
dc.subject.keywordPlus | ANTITHROMBOTIC THERAPY | - |
dc.subject.keywordPlus | ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | P2Y(12) INHIBITOR | - |
dc.subject.keywordPlus | AMERICAN-COLLEGE | - |
dc.subject.keywordPlus | ASIAN PATIENTS | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | GUIDELINE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | Myocardial infarction | - |
dc.subject.keywordAuthor | Ticagrelor | - |
dc.subject.keywordAuthor | Prasugrel | - |
dc.subject.keywordAuthor | Percutaneous coronary intervention | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.